The decline in vaccination rates during the SARS-CoV-2 pandemic could lead to global outbreaks of communicable infectious diseases.
All articles by David C. Helfgott, MD
The US Food and Drug Administration has issued an emergency use authorization for the use of remdesivir in the treatment of COVID-19 infection in patients with oxygen saturation on room air ≤94% requiring supplemental oxygen, mechanical ventilation, or extracorporeal membrane oxygenation.
It is certainly too early to know if there will be any seasonal variation to SARS-CoV-2 infection, and there is no reason to specifically compare this virus with the seasonal behavior of influenza virus or to other seasonal respiratory viruses.
Although influenza virus and respiratory syncytial virus are considered to be spread by droplets and aerosol transmission, the mode of respiratory transmission of SARS-CoV-2 is not completely understood.
Hydroxychloroquine is a less-toxic metabolite of the antimalarial drug chloroquine and is used as an immunomodulator for the treatment of autoimmune diseases.
In this review, David C. Helfgott, MD, editorial advisory board member for Infectious Disease Advisor, focuses on infectious complications from the use of monoclonal antibodies for malignancy.
The risk for infection and malignancy associated with biologic use complicates the management of patients with a deficient immune system. Equip yourself with the information needed to effectively manage these complex patients.